Thue W. Schwartz

Thue W. Schwartz is a Professor at the Faculty of Health and Medical Sciences, University of Copenhagen, where he leads the Schwartz Group at the Center for Basic Metabolic Research (CBMR). His research focuses on appetite regulation and the development of obesity drugs, with particular interest in how hunger and satiety signals are transmitted from the stomach to the brain.

Professor Schwartz's primary research areas include molecular pharmacology, obesity research, appetite regulation, GPCR signaling, drug development for metabolic disorders, and neuroendocrinology. His work bridges basic science with clinical applications, aiming to develop novel therapeutic approaches for metabolic diseases. He investigates the molecular mechanisms of receptor signaling, neural circuits involved in appetite control, and translational approaches to obesity treatment, with significant focus on targeting receptors like FFA4 and GLP-1 for therapeutic interventions.

Professor Schwartz is the co-founder of 7TM Pharma, where he also serves as research director. The company focuses on the discovery and development of new obesity drugs, with the first candidates - stemming from research at the University of Copenhagen - currently being tested. His work demonstrates strong industry-academia collaboration aimed at translating basic research findings into clinical applications. His research has garnered significant attention across social media platforms and news outlets, with multiple publications being widely discussed in scientific communities.